Identification of Small Molecules That Inhibit the Interaction of TEM8 with Anthrax Protective Antigen Using a FRET Assay

Overview

Journal J Biomol Screen

Publisher Sage Publications

Date 2013 Mar 13

PMID 23479355

Citations 9

Authors

Lorna M Cryan

Kaiane A Habeshian

Thomas P Caldwell

Meredith T Morris

P Christine Ackroyd

Kenneth A Christensen

Michael S Rogers

Affiliations

Soon will be listed here.

Abstract

Tumor marker endothelial 8 (TEM8) is a receptor for the protective antigen (PA) component of anthrax toxin. TEM8 is upregulated on endothelial cells lining the blood vessels within tumors, compared with normal blood vessels. A number of studies have demonstrated a pivotal role for TEM8 in developmental and tumor angiogenesis. We have also shown that targeting the anthrax receptors with a mutated form of PA inhibits angiogenesis and tumor formation in vivo. Here we describe the development and testing of a high-throughput fluorescence resonance energy transfer assay to identify molecules that strongly inhibit the interaction of PA and TEM8. The assay we describe is sensitive and robust, with a Z' value of 0.8. A preliminary screen of 2310 known bioactive library compounds identified ebselen and thimerosal as inhibitors of the TEM8-PA interaction. These molecules each contain a cysteine-reactive transition metal, and complementary studies indicate that their inhibition of interaction is due to modification of a cysteine residue in the TEM8 extracellular domain. This is the first demonstration of a high-throughput screening assay that identifies inhibitors of TEM8, with potential application for antianthrax and antiangiogenic diseases.

Citing Articles

AZIN1 RNA editing alters protein interactions, leading to nuclear translocation and worse outcomes in prostate cancer.

Ghalali A, Wang L, Stopsack K, Rice J, Wu S, Wu C Exp Mol Med. 2022; 54(10):1713-1726.

PMID: 36202978 PMC: 9636422. DOI: 10.1038/s12276-022-00845-6.

Capillary morphogenesis gene 2 (CMG2) mediates growth factor-induced angiogenesis by regulating endothelial cell chemotaxis.

Cryan L, Tsang T, Stiles J, Bazinet L, Lee S, Garrard S Angiogenesis. 2022; 25(3):397-410.

PMID: 35212873 PMC: 9250616. DOI: 10.1007/s10456-022-09833-w.

Toxicology and pharmacology of synthetic organoselenium compounds: an update.

Nogueira C, Barbosa N, Rocha J Arch Toxicol. 2021; 95(4):1179-1226.

PMID: 33792762 PMC: 8012418. DOI: 10.1007/s00204-021-03003-5.

Selenium and selenoproteins in viral infection with potential relevance to COVID-19.

Zhang J, Saad R, Taylor E, Rayman M Redox Biol. 2020; 37:101715.

PMID: 32992282 PMC: 7481318. DOI: 10.1016/j.redox.2020.101715.

The selenium-containing drug ebselen potently disrupts LEDGF/p75-HIV-1 integrase interaction by targeting LEDGF/p75.

Zhang D, Yan H, Xu X, Xu L, Yin Z, Chang S J Enzyme Inhib Med Chem. 2020; 35(1):906-912.

PMID: 32228103 PMC: 7170385. DOI: 10.1080/14756366.2020.1743282.

References

St Croix B, Rago C, Velculescu V, Traverso G, Romans K, Montgomery E . Genes expressed in human tumor endothelium. Science. 2000; 289(5482):1197-202. DOI: 10.1126/science.289.5482.1197. View

Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E . Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med. 2008; 14(11):1236-46. PMC: 2593632. DOI: 10.1038/nm.1877. View

Fernando S, Fletcher B . Targeting tumor endothelial marker 8 in the tumor vasculature of colorectal carcinomas in mice. Cancer Res. 2009; 69(12):5126-32. DOI: 10.1158/0008-5472.CAN-09-0725. View

Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T . Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke. 1998; 29(1):12-7. DOI: 10.1161/01.str.29.1.12. View

Nanda A, Carson-Walter E, Seaman S, Barber T, Stampfl J, Singh S . TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res. 2004; 64(3):817-20. DOI: 10.1158/0008-5472.can-03-2408. View

Rogers M, Christensen K, Birsner A, Short S, Wigelsworth D, Collier R . Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth. Cancer Res. 2007; 67(20):9980-5. DOI: 10.1158/0008-5472.CAN-07-0829. View

Scobie H, Thomas D, Marlett J, Destito G, Wigelsworth D, Collier R . A soluble receptor decoy protects rats against anthrax lethal toxin challenge. J Infect Dis. 2005; 192(6):1047-51. DOI: 10.1086/432731. View

Verma K, Gu J, Werner E . Tumor endothelial marker 8 amplifies canonical Wnt signaling in blood vessels. PLoS One. 2011; 6(8):e22334. PMC: 3148219. DOI: 10.1371/journal.pone.0022334. View

Tozer E, Liddington R, Sutcliffe M, Smeeton A, Loftus J . Ligand binding to integrin alphaIIbbeta3 is dependent on a MIDAS-like domain in the beta3 subunit. J Biol Chem. 1996; 271(36):21978-84. DOI: 10.1074/jbc.271.36.21978. View

10.

Bradley K, Mogridge J, Jonah G, Rainey A, Batty S, Young J . Binding of anthrax toxin to its receptor is similar to alpha integrin-ligand interactions. J Biol Chem. 2003; 278(49):49342-7. DOI: 10.1074/jbc.M307900200. View

11.

Zhang , Chung , OLDENBURG . A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 2000; 4(2):67-73. DOI: 10.1177/108705719900400206. View

12.

Rmali K, Puntis M, Jiang W . TEM-8 and tubule formation in endothelial cells, its potential role of its vW/TM domains. Biochem Biophys Res Commun. 2005; 334(1):231-8. DOI: 10.1016/j.bbrc.2005.06.085. View

13.

Martchenko M, Jeong S, Cohen S . Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin. Proc Natl Acad Sci U S A. 2010; 107(35):15583-8. PMC: 2932583. DOI: 10.1073/pnas.1010145107. View

14.

Terentis A, Freewan M, Plaza T, Raftery M, Stocker R, Thomas S . The selenazal drug ebselen potently inhibits indoleamine 2,3-dioxygenase by targeting enzyme cysteine residues. Biochemistry. 2009; 49(3):591-600. DOI: 10.1021/bi901546e. View

15.

Rogers M, Cryan L, Habeshian K, Bazinet L, Caldwell T, Ackroyd P . A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. PLoS One. 2012; 7(6):e39911. PMC: 3386954. DOI: 10.1371/journal.pone.0039911. View

16.

Fu S, Tong X, Cai C, Zhao Y, Wu Y, Li Y . The structure of tumor endothelial marker 8 (TEM8) extracellular domain and implications for its receptor function for recognizing anthrax toxin. PLoS One. 2010; 5(6):e11203. PMC: 2887854. DOI: 10.1371/journal.pone.0011203. View

17.

Carson-Walter E, Watkins D, Nanda A, Vogelstein B, Kinzler K, St Croix B . Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 2001; 61(18):6649-55. View

18.

Werner E, Kowalczyk A, Faundez V . Anthrax toxin receptor 1/tumor endothelium marker 8 mediates cell spreading by coupling extracellular ligands to the actin cytoskeleton. J Biol Chem. 2006; 281(32):23227-36. DOI: 10.1074/jbc.M603676200. View

19.

Zembowicz A, Hatchett R, Radziszewski W, Gryglewski R . Inhibition of endothelial nitric oxide synthase by ebselen. Prevention by thiols suggests the inactivation by ebselen of a critical thiol essential for the catalytic activity of nitric oxide synthase. J Pharmacol Exp Ther. 1993; 267(3):1112-8. View

20.

Michishita M, Videm V, Arnaout M . A novel divalent cation-binding site in the A domain of the beta 2 integrin CR3 (CD11b/CD18) is essential for ligand binding. Cell. 1993; 72(6):857-67. DOI: 10.1016/0092-8674(93)90575-b. View